Topic: Clinical Trial for Metastatic TNBC Now Recruiting

Forum: Clinical Trials, Research News, Podcasts, and Study Results — Share your research articles, interpretations and experiences here. Let us know how these studies affect you and your decisions.

Posted on: May 22, 2022 10:30PM

Posted on: May 22, 2022 10:30PM

wc3 wrote:

CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer Description

This phase I trial tests the safety, side effects, and best dose of CF33-hNIS-antiPDL1 in treating patients with triple negative breast cancer that has spread to other places in the body (metastatic). CF33-hNIS-antiPDL1 is an oncolytic virus. This is a virus that is designed to infect tumor cells and break them down.


Pathologic complete response (pCR) to chemotherapy. Dx 2018, IDC, Left, 3cm, Grade 3, ER+/PR+, HER2- Chemotherapy 6/1/2018 Carboplatin (Paraplatin), Taxotere (docetaxel) Surgery 11/15/2018 Lymph node removal; Lymph node removal (Left): Sentinel; Mastectomy; Mastectomy (Left); Mastectomy (Right); Reconstruction (Left): Tissue Expander; Reconstruction (Right): Tissue Expander Hormonal Therapy Arimidex (anastrozole), Zoladex (goserelin) Targeted Therapy Perjeta (pertuzumab) Targeted Therapy Herceptin (trastuzumab) Hormonal Therapy Tamoxifen pills (Nolvadex, Apo-Tamox, Tamofen, Tamone) Surgery Reconstruction (Left): Silicone implant; Reconstruction (Right): Silicone implant
Log in to post a reply
Scroll to top button